Pfizer/BioNTech’s COVID-19 vaccine appears to be 100% effective at preventing adolescent infections; Vyxeos approved for pediatric secondary acute myeloid leukemia (AML); study results show a 62% drop in pediatric respiratory illness over the past year.
At a time when weekly COVID-19 cases in the United States are on the rise again, up 15% alone from 2 weeks ago, Pfizer and BioNTech have released data from a trial investigating their vaccine’s use among adolescents aged 12 to 15 years. These data, which have yet to be peer reviewed, show higher antibody responses vs 16-to-25-year-olds from a previous trial, as well as no infections or serious adverse effects among the 2260 adolescents who participated, reports The New York Times. The placebo group had 18 cases of infection. At present, even with 16% of adults fully vaccinated, experts warn that herd immunity will not be possible without inoculating children.
Jazz Pharmaceuticals’ Vyxeos (daunorubicin/cytarabine) has been approved by the FDA for use among children 1 year and older with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, the company is reporting. The combination anthracycline topoisomerase/nucleoside metabolic inhibitor was approved based on, and its safety supported by, data from the phase 1/2 AAML1421 and phase 1 CPX-MA-1201 trials. Common adverse events include bleeding events, constipation, irregular heartbeat, and sleep disorders. Other daunorubicin and/or cytarabine-containing products cannot be used in place of Vyxeos.
A new report in Journal of Hospital Medicine shows that respiratory illnesses are down 62% over the past year, according to data from 44 children’s hospitals included in a study from Vanderbilt University Medical Center. In addition, the data show just 1 flu-related death compared with the usual annual toll of 100 to 200 deaths, and experts credit these numbers to social distancing measures and parents not sending their sick children to school, notes Kaiser Health News. Flu-related numbers are also down among adults, and deaths among this age group will be measured in hundreds, vs the usual thousands, this year, according to the CDC.
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Review Explores Link Between Tumor Burden, CAR T-Cell Therapy Efficacy
November 17th 2023A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.
Read More
High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds
November 3rd 2023A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.
Read More